Welcome to BSAZ,
where we stand at the forefront of synthetic biology, pioneering a healthier, more sustainable world together.
Hangzhou Baisansheng Biotechnology Co., Ltd. (BSAZ), since its establishment in 2013, has consistently stood at the forefront of synthetic biology, dedicated to becoming an innovation leader in the field of bio-based products.
Its core R&D team comprises talents from top global institutions such as Zhejiang University, ETH Zurich (Swiss Federal Institute of Technology Zurich), and the Max Planck Institute in Germany. Leveraging cutting-edge synthetic biology technology as its foundation, BSAZ drives the commercial application of diverse innovative products across critical sectors including pharmaceuticals, chemicals, new materials, food, agriculture, and energy.
Currently, its headquarters and R&D center are located in Hangzhou, with four production bases situated in Hangzhou, Huzhou, Huangshan, and Fuyang, respectively.
BSAZ has successfully completed its Series B funding round, raising hundreds of millions of RMB, and has secured investments from renowned institutions, including the Tsinghua Yangtze River Delta Research Institute's investment platform.
BSAZ's current business primarily focuses on the bio-based pentamethylenediamine (BDA) industrial chain. Its products include the monomer bio-based pentamethylenediamine and long-chain dicarboxylic acids, extending downstream to bio-based piperidine, bio-based polyamide, and more. The company also continuously explores thermoplastic fiber-reinforced bio-based composite materials and their market application technologies. In the future, upon project implementation, BSAZ plans to achieve full industrial chain coverage, including bio-based polyamides and their corresponding bio-based monomers. Leveraging its existing technology and market position, the product and market share for its series of bio-based monomers, bio-based polyamides, and their composite materials are expected to continue expanding.
Synthetic Biology: Unlocking a New Chapter in Compound Synthesis, a Blue Ocean Market Emerges with AI at the Helm
Synthetic biology is a novel field of biological research that integrates science and engineering. It involves using chemically or biochemically synthesized DNA or protein biological components to create standardized component libraries through engineering methods. This allows for the creation of biological modules, networks, systems, and even entire organisms (chassis cells) with novel characteristics or enhanced performance. Ultimately, it enables the synthesis of chemicals, pharmaceuticals, biomaterials, and other substances using renewable resources such as starch and carbon dioxide as raw materials, meeting the demands of diverse application fields.
With advancements in industrial technology, synthetic biomanufacturing has garnered continuous high attention and accelerated deployment from major global economies in recent years. The Organisation for Economic Co-operation and Development (OECD) predicts that by 2030, 35% of chemicals and other industrial products will originate from biomanufacturing. Biomanufacturing's contribution to the bioeconomy is projected to reach 39%, surpassing bio-agriculture (36%) and biopharmaceuticals (25%). Moreover, 25% of organic chemicals and 20% of fossil fuels are expected to be replaced by bio-based chemicals.
